Lenvatinib Impurity 12 | CAS 2712290-12-3 - Request Quote
Lenvatinib Impurity 12
| SZ CAT No: | SZ-L038015 |
| CAS No | 2712290-12-3 |
| Mol.F. | C17H13ClN2O4 |
| Mol.Wt. | 344.8 |
| Inv. Status | In Stock |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Lenvatinib Impurity 12 is chemically 4-(4-Amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxylic acid. Lenvatinib Impurity 12 is supplied with detailed characterization data compliant with regulatory guideline. Lenvatinib Impurity 12 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Lenvatinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 2712290-12-3
Purchase 2712290-12-3
Order 2712290-12-3
Enquire 2712290-12-3
price of 2712290-12-3
2712290-12-3 Supplier
2712290-12-3 Manufacturer
2712290-12-3 Exporter
buy high quality Lenvatinib Impurity 12
Purchase Lenvatinib Impurity 12
Lenvatinib Impurity 12 suppliers
Lenvatinib Impurity 12 manufacturers
Lenvatinib Impurity 12 price
Order Lenvatinib Impurity 12
Enquire Lenvatinib Impurity 12
Lenvatinib Impurity 12 cost
Lenvatinib Impurity 12 Supplier
Lenvatinib Impurity 12 Distributor
Lenvatinib Impurity 12 for Method Validation
Lenvatinib Reference Standard
Lenvatinib Impurity 12 for ANDA Filing
Lenvatinib Impurity 12 for Forced Degradation Studies
Lenvatinib Impurity 12 Identification Standards
Lenvatinib Impurity 12 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.